Incyte Corporation (INCY)
| Market Cap | 13.69B |
| Revenue (ttm) | 4.08B |
| Net Income (ttm) | 32.48M |
| Shares Out | 192.65M |
| EPS (ttm) | 0.15 |
| PE Ratio | 478.81 |
| Forward PE | 12.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,137,082 |
| Open | 70.66 |
| Previous Close | 70.56 |
| Day's Range | 70.25 - 71.67 |
| 52-Week Range | 50.35 - 83.95 |
| Beta | 0.71 |
| Analysts | Buy |
| Price Target | 75.47 (+6.22%) |
| Earnings Date | Oct 29, 2024 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast ... [Read more]
Financial Performance
In 2023, Incyte's revenue was $3.70 billion, an increase of 8.87% compared to the previous year's $3.39 billion. Earnings were $597.60 million, an increase of 75.42%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $75.47, which is an increase of 6.22% from the latest price.
News
Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study
Incyte (INCY) led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.
Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock.
The biopharmaceutical company provided disappointing updates on two research studies.
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
On Monday, Incyte Corporation INCY announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs.
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami. The presen...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. New product approvals, like Niktimvo, should diversify Incyte's revenue and reduce r...
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
On Tuesday, Incyte Corporation INCY reported third-quarter revenue of $1.14 billion, up 24% year over year, beating the consensus of $1.08 billion.
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim's Inaugural Healthcare Inno...
Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q3 2024 Results Conference Call October 29, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Exec...
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
On Tuesday, Incyte Corporation INCY reported third-quarter revenue of $1.14 billion, up 24% year over year and beating the consensus of $1.08 billion.
Incyte raises 2024 sales forecast for top-selling drug Jakafi
Incyte beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong.
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs.
Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SCTopEmployers--Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List.
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program.
Incyte to Report Third Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2...
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the EADV 2024 Congress.
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment – – ...
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Truist Securities has downgraded Incyte Corporation INCY, noting Jakafi's (ruxolitinib) patent loss approaching in 2028.
Doğuş Technology and Doğuş Construction Participate in ConteQ Expo 2024 with Innovative Projects
DOHA, Qatar--(BUSINESS WIRE)--Doğuş Technology, one of Turkey's leading tech companies, will showcase its innovative, technology-driven solutions for the construction industry at ConteQ Expo 2024, alo...
Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.
Incyte's Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's Retifanlimab (Zynyz) Extends Progression-Free Survival in Patients with SCAC; Data Featured at ESMO 2024 Presidential Symposium.
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at ESMO Congress 2024.
Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Incyte Corporation reported positive results achieved from Phase 3 study using Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma. Supplemental Biologics License Applic...